• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Non-small cell lung cancer - Articles and news items

study-roche

Roche’s cancer immunotherapy drug has longer OS vs. chemotherapy

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events were consistent with what has […]

approval-pfizer-lung-cancer

EU approval for Pfizer’s non-small cell lung cancer drug

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The drug exhibited marked anti-tumour activity in patients with ROS1-positive advanced NSCLC and met its primary endpoint of ORR. Tumours were tested for ROS1 rearrangements by laboratory-developed break-apart fluorescence in situ hybridization (FISH) (96%) or real-time polymerase chain reaction (RT-PCR) (4%) assay…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +